Login to Your Account



CNS-Focused Company Reverses into Public Domain, Raises $60M

By Peter Winter
Editor, BioWorld Insight

Tuesday, September 3, 2013
New York-based Intra-Cellular Therapies Inc. (ITI), a biopharmaceutical company focused on the development of therapeutics for CNS disorders, generated gross proceeds of approximately $60 million from a private placement, which included the sale of approximately 18.9 million shares of its common stock to new and existing investors and approximately $15.3 million in bridge notes that converted into common stock at the closing.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription